Ludger News

July/August 2020



Ludger Glycan Analysis Services

Announcing the Launch of a Search Function for Ludger Product Certificates

We are pleased to announce the launch of our brand-new webpage for Ludger Product Certificates Search with immediate effect.

A certificate of analysis (CofA) is a document indicating that the product meets its product specifications. The CofA includes test results for each individual batch of a product that is obtained using our quality control procedure.

We wanted to make it easier and faster to locate a CofA on our website. The new webpage gives you the ability to search for, view, and download CofAs. To retrieve a CofA, please enter the product batch (or lot) number found on the product label.



For a Certificate of Analysis/Conformity please visit: www.ludger.com/product-certificates
We sincerely hope you enjoy navigating through our new webpage and if you have any suggestions or feedback please E-mail us.

Ludger Glyco-Tools: System Suitability Standards

Ludger provides a range of system suitability standards for different applications including the analysis of sialic acids (SA), monosaccharides (Mono), N-glycans (N) and O-glycans (O). We offer purified unlabelled, 2-AA, 2-AB, APTS, procainamide labelled or permethylated glycan standards, quantitative monosaccharides and sialic acid standards, quantitative glycopeptide standards and glycoprotein standards.

They can be used for:

- Process controls for release, labelling and analysis
- System suitability testing for MS, (u)HPLC and CE
- GU (glucose unit) calibration for (u)HPLC
- Structure identification
- Quantitation
- Exoglycosidase sequencing (positive and negative controls)

Please visit our Products page for a full listing of the system suitability standards and controls we have available.



Ludger System Suitability Standards and Controls - Summary Table

If you have any questions or to request a quotation, please contact: info@ludger.com

---

Announcing the Launch of the New Webpages for Ludger Glycan Analysis Services

We are very excited at Ludger to launch our newly designed Glycan Analysis Services webpages with immediate effect.

The detailed knowledge of glycan structures is invaluable for a better understanding of their biological functions. Glycans can have a significant effect on the clinical safety and efficacy of biopharmaceuticals. Issues with glycans have caused great financial, legal and regulatory problems for those companies who have not dealt effectively with their product's glycosylation.

Ludger offers custom analytical services to suit your individual requirements and has been doing so since 1999. Ludger's Glycan Analysis Team has many years of expertise in analysing glycosylation from a variety of sample types including:

- Biopharmaceuticals: monoclonal antibodies (mAbs), glycoprotein hormones (e.g. follicle stimulating hormone (FSH) and erythropoietin (EPO), Fc fusion proteins, vaccines
- Cells: mammalian cell lines, bacterial cell components
- Biological fluids, tissues and others

Ludger's Glycan Analysis Services include: Quantitative Sialic Acid Analysis, Quantitative Monosaccharide Analysis, N- and O-glycan profiling and characterization, site occupancy and site-specific glycosylation analysis.

The new webpages have been designed with an intuitive layout for ease of navigation and the menu options are designed to guide you to the most appropriate glycoprofiling programme.

We have incorporated valuable information regarding each glycoprofiling program/module.

For more information please visit the Glycan Analysis Services pages. If you have any questions or to request a Study Proposal and quotation, please contact us at info@ludger.com or Dr Radoslaw Kozak directly at rad.kozak@ludger.com

We sincerely hope you enjoy navigating through our new Glycan Analysis Services webpages and if you have any suggestions or feedback please E-mail us.

Publication in Cellular and Molecular Life Sciences: Discovery of Antennary Fucosidase Capable of Removing Fucose from Sialylated Glycans

A successful collaboration between Ludger and The Gut Microbes and Health Institute Strategic Programme at the Quadram Institute has resulted in the publishing of an article in Cellular and Molecular Life Sciences titled "**Fucosidases from the human gut symbiont *Ruminococcus gnavus***".

Ludger's contribution included detailed characterization of the activity profile of the fucosidases which was made possible by LC-MS analysis of procainamide labelled glycan products of enzymatic reactions. This study has lead to the discovery of a novel fucosidase with unique specificity, capable of removing α1-3,4 fucose from sialylated glycan epitopes (like Sialyl Lewis X/A). The discovery will facilitate future research into Lewis epitope-associated diseases like cancers and diabetes.



Figure 4D - Model of the orientation and conformation of sLeX bound to R. gnavus E1_10125 proposed by MD simulations

This well characterised fucosidase will soon be available as part of the Ludger exoglycosidase enzymes portfolio. Please enquire at info@ludger.com for more information.

Visit our Procainamide webpage for more information on how to characterise glycans using LC-MS. For further information about this article visit our Publications webpage.

Osmond Rebello received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 722095 for the GlySign project. The enzyme was produced through funding of the Glycoenzymes for Bioindustries collaboration from the BBSRC, EPSRC and Innovate UK.

Join our Glycotechnology News Service

Subscribe